Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane

Trial Profile

Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane

Recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Aug 2018

At a glance

  • Drugs Tesetaxel (Primary) ; Capecitabine
  • Indications Advanced breast cancer; Male breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CONTESSA
  • Sponsors Odonate Therapeutics
  • Most Recent Events

    • 05 Jun 2018 Trial design data presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 16 May 2018 According to an Odonate Therapeutics media release, data will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.
    • 01 Dec 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top